U.S. Markets closed
  • S&P 500

    3,310.11
    +39.08 (+1.19%)
     
  • Dow 30

    26,659.11
    +139.16 (+0.52%)
     
  • Nasdaq

    11,185.59
    +180.72 (+1.64%)
     
  • Russell 2000

    1,561.58
    +18.30 (+1.19%)
     
  • Crude Oil

    36.08
    -1.31 (-3.50%)
     
  • Gold

    1,868.20
    -11.00 (-0.59%)
     
  • Silver

    23.34
    -0.01 (-0.06%)
     
  • EUR/USD

    1.1677
    -0.0073 (-0.6189%)
     
  • 10-Yr Bond

    0.8350
    +0.0540 (+6.91%)
     
  • Vix

    37.59
    -2.69 (-6.68%)
     
  • GBP/USD

    1.2931
    -0.0056 (-0.4332%)
     
  • USD/JPY

    104.5740
    +0.2730 (+0.2617%)
     
  • BTC-USD

    13,465.50
    -77.41 (-0.57%)
     
  • CMC Crypto 200

    264.69
    +22.01 (+9.07%)
     
  • FTSE 100

    5,581.75
    -1.05 (-0.02%)
     
  • Nikkei 225

    23,331.94
    -86.57 (-0.37%)
     

MYOKARDIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MYOK and Encourages Investors to Contact the Firm

Bragar Eagel & Squire
·2 mins read

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of MyoKardia, Inc. (NASDAQ: MYOK) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Bristol Myers Squibb (NYSE: BMY).

Click here to learn more and participate in the action.

On October 5, 2020, MyoKardia announced that it had signed an agreement to be acquired by Bristol Myers Squibb for approximately $13.1 billion. Pursuant to the merger agreement, MyoKardia stockholders will receive $225 in cash for each share of MyoKardia common stock owned. The deal is scheduled to close in the fourth quarter of 2020.

Bragar Eagel & Squire is concerned that MyoKardia’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for MyoKardia’s stockholders.

If you own shares of MyoKardia and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
investigations@bespc.com
www.bespc.com